Facebook As A CRO: Social Networks Become Factor In Clinical Trial Designs
Executive Summary
Drug companies soon may have to account for the effects of patients’ social networking when designing studies, a Pfizer official said.
You may also be interested in...
Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
People Power: How The Crowd May Shape The Funding And Development Of Drugs
Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.
Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies
NIH plans to select two dozen groups to participate in a Global Rare Disease Patient Registry pilot project, which FDA hopes will lead to a better understanding of the conditions and speed drug development.